Cell Therapeutics shares fell 10.7 percent Monday after the Food and Drug Administration ordered it to stop enrolling patients in its clinical trial of a drug candidate for blood-related cancers.
The Seattle biotechnology company said the halt was prompted by the death of a patient from myocarditis, an inflammation of the heart muscle wall. The patient was over 70, and was being treated with the company’s drug Tosedostat in combination with another drug.
The FDA has requested more information on patients and adverse events in the clinical trial. Cell Therapeutics can’t enroll new patients until the agency gives the go-ahead.
Cell Therapeutics stock closed at $1.09 Monday, down 13 cents.
- 2 killed, half-million lose power in Seattle-area windstorm
- High winds stall firefighting efforts, fuel Tunk Block, Lime Belt fires
- Jack Zduriencik’s M’s legacy: More than 3 dozen departed managers, coaches, scouts, staffers
- Wet weekend ahead, with high winds and heavy rain expected
- Seahawks’ third exhibition game may be a dress rehearsal, but it does have significance